Burgdorf/New York, 28.08.2018, 7.00 a.m. – JDRF, the leading global organization funding type 1 diabetes (T1D) research, has announced a partnership with Ypsomed, a Switzerland-based developer and manufacturer of injection and infusion systems, as part of JDRF’s Open-Protocol Automated Insulin Delivery (AID) Systems Initiative. The objective of the project is the development and regulatory approval of the next-generation mylife™ YpsoPump® insulin pump supporting incorporation into an automated insulin delivery (AID) system via open-protocol communication with third-party smartphone-based apps and/or other devices.
Through a two-year grant, JDRF will contribute financial resources to help accelerate Ypsomed’s development of the next-generation, fully interoperable mylife™ YpsoPump® insulin pump system that will support open-protocol-enabled AID by smartphone-based applications and/or other devices. This development will allow seamless connectivity with the mylife™ YpsoPump® via secure, well documented and verified communication protocols.
“JDRF is committed to supporting technological innovation which will enable type 1 diabetes families to use an open-protocol approach safely,” said JDRF Chief Mission Officer Aaron Kowalski, Ph.D. “We are excited to partner with companies, such as Ypsomed, that share in our commitment to ensure people with diabetes have access to tools that improve their lives as we drive towards a cure.”
Thanks to its icon-based menu and touchscreen, the mylife™ YpsoPump® is extremely easy and intuitive to operate. Bluetooth® low energy integration enables wireless connection to the mylife™ Software and the mylife™ App. The app features a bolus calculator, logbook functionality with detailed reports and cloud connectivity. With the wireless linking of the insulin pump, blood glucose meter and therapy management solution, Ypsomed offers a basic connected diabetes management solution already today. Over the next twelve months, Ypsomed plans to integrate CGM data into the app and to establish two-way communication between the insulin pump and the app. Participation in JDRF’s Open-Protocol Automated Insulin Delivery (AID) Systems Initiative is thus the next logical technical development and yet another contribution to give people with T1D expanded freedom of choice in their therapy options for AID systems. The next-generation mylife™ YpsoPump® supporting AID via open-protocol communication is expected to improve therapeutic outcomes and reduce the burden for people with T1D significantly.
Simon Michel, Ypsomed CEO, comments on the new partnership: “Together with partners such as JDRF, we are convinced that we are able to establish an open platform that will better allow for individualized automated insulin pump therapy. We aim to support interoperability to enable users to choose the most appropriate solution for their therapy needs. The initiative also reflects our awareness of major treatment improvements related to digitization. With our mylife™ YpsoPump® we make a relevant contribution.”
The mylife™ YpsoPump® system has been launched broadly in 2017. The product is currently available in 16 countries and is being launched in eight more countries worldwide, including Canada in 2018 and USA in 2019. The submission to the US Food and Drug Administration (FDA) is currently ongoing.
For further information, please contact Thomas Kutt, Head of Investor Relations at Ypsomed Holding AG, at the telephone number +41 34 424 35 55 or by e-mail (firstname.lastname@example.org).
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1’500 employees. Additional information is available under www.ypsomed.com.
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF
Type 1 diabetes (T1D) is an autoimmune disease in which a person’s pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. Its onset has nothing to do with diet or lifestyle. There is nothing you can do to prevent T1D, and—at present—nothing you can do to get rid of it.
Disclaimer: The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ypsomed AG is under license. Other trademarks and trade names are those of their respective owners.